Tag Archives: Reviews

Previews: New Scientist Magazine – December 11

Previews: Times Literary Supplement – December 10

Shakespeare & Company: ‘Matrix’ Author Lauren Groff Interview (Podcast)

Lauren Groff is the author of six books of fiction, the most recent the novel MATRIX (September 2021). Her work has won The Story Prize, the ABA Indies’ Choice Award, and France’s Grand Prix de l’Héroïne, was a three time finalist for the National Book Award for Fiction and twice for the Kirkus Prize, and was shortlisted for the National Book Critics Circle Prize, the Southern Book Prize, and the Los Angeles Times Prize.

She has received fellowships from the Guggenheim Foundation and the Radcliffe Institute for Advanced Study, and was named one of Granta’s Best of Young American Novelists. Her work has been translated into over thirty languages. She lives in Gainesville, Florida.

Science: New Scientist Weekly Podcast – DEC 2

Front Covers: Science Magazine – December 3

Medicine: The Mayo Clinic Explains Lymphoma (Video)

Learning about lymphoma can be intimidating. Let our experts walk you through the facts, the questions, and the answers to help you better understand this condition. 

Video timeline: 0:24 What is Lymphoma?  1:20 Types of Lymphoma 2:04 Who gets Lymphoma? 2:48 Risk factors 3:30 Symptoms 4:10 How is Lymphoma diagnosed?  5:07 Treatment options   6:11 Coping methods/ What now?  7:09 Ending   

For more reading visit: https://mayocl.in/3xThjs7

Previews: The Scientist Magazine – December 2021

Museum Exhibits: ‘Dürer’s Journeys – Travels of a Renaissance Artist’ (Video)

Albrecht Dürer’s drawings, paintings and prints make up some of the most iconic images in the history of art and have influenced generations of artists. Through paintings, drawings, prints, and letters, our exhibition ‘Dürer’s Journeys: Travels of a Renaissance Artist’ brings to life this art history megastar and the people and places he visited. ‘The Credit Suisse Exhibition: Dürer’s Journeys: Travels of a Renaissance Artist’ Until 27 February 2022

Covid-19: Why Omicron Concerns Scientists (WSJ)

The B.1.1.529 variant was first reported to WHO from South Africa on 24 November 2021. The epidemiological situation in South Africa has been characterized by three distinct peaks in reported cases, the latest of which was predominantly the Delta variant. In recent weeks, infections have increased steeply, coinciding with the detection of B.1.1.529 variant. The first known confirmed B.1.1.529 infection was from a specimen collected on 9 November 2021.

This variant has a large number of mutations, some of which are concerning. Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs. The number of cases of this variant appears to be increasing in almost all provinces in South Africa. Current SARS-CoV-2 PCR diagnostics continue to detect this variant. Several labs have indicated that for one widely used PCR test, one of the three target genes is not detected (called S gene dropout or S gene target failure) and this test can therefore be used as marker for this variant, pending sequencing confirmation. Using this approach, this variant has been detected at faster rates than previous surges in infection, suggesting that this variant may have a growth advantage.